Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89886 | 0.92 | CTSK (0.40) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL23138085 | 0.86 | USP2 (0.40) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL6187275 | 0.86 | USP2 (0.40) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL17830842 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL23071129 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL1476907 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL17176669 | 0.83 | JAK2 (0.44) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL23283111 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL20571615 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL10529377 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1942893-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | USP2 2988/4885SMN1; SMN2 2212/4885CTSK 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.